ArriVent BioPharma, Inc.
AVBPDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
furmonertinib 240 mg oral, daily
Metastatic Non-Small Cell Lung Cancer
Firmonertinib
Non-Small-Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
furmonertinib 240 mg oral, daily | Phase 3 | Metastatic Non-Small Cell Lung Cancer | - | - |
Firmonertinib | Phase 3 | Non-Small-Cell Lung Cancer | - | - |
Frequently asked questions
What is in ArriVent BioPharma, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in ArriVent BioPharma, Inc.'s (AVBP) pipeline across Phase 3. Its lead program is furmonertinib 240 mg oral, daily (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is ArriVent BioPharma, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for ArriVent BioPharma, Inc. (AVBP) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track AVBP biotech catalysts?→
Add AVBP to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow ArriVent BioPharma, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.